DURHAM, NC — A secondary analysis of the ARISTOTLE trial supports using the standard 5-mg twice-daily dose of apixaban (Eliquis, Bristol-Myers Squibb) in patients with atrial fibrillation (AF ...

heart ecg arrhythmia For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

In A-fib patients selected using established dose-reduction criteria, the 2.5-mg twice daily dose of apixaban (Eliquis; Bristol-Myers Squibb) provides protection against stroke and death versus ...

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

“The standard dose of apixaban is safe in people with one dose-reduction criterion and—as is labeled in the package insert—should be the dose that’s used in [those patients],” he said. Further ...

In the ARISTOTLE trial of apixaban versus warfarin for stroke prevention in patients with atrial fibrillation, those with two or more dose-reduction criteria (aged ≥80 years, weight ≤60 kg ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to ... 6% respectively), a statistically significant reduction in favor of the reduced dose.

Reduction in ICH ... with rivaroxaban having the advantage of a once-daily dose, whereas dabigatran and apixaban are given twice daily. Goldstein pointed out that renal insufficiency is an ...

Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa ...

The addition of apixaban, at a dose of 5 mg twice daily ... the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb ...